Chris Bahl
@cdbahl.com
Thanks for the fun conversation Ingmar Schuster, and for the opportunity to share more about what we're building at @aiproteins.com!
youtu.be/7O0s5AY46U0
youtu.be/7O0s5AY46U0
Chris Bahl on the Conundrum of Biotech Platforms
YouTube video by Provolut
youtu.be
November 21, 2025 at 8:18 PM
Thanks for the fun conversation Ingmar Schuster, and for the opportunity to share more about what we're building at @aiproteins.com!
youtu.be/7O0s5AY46U0
youtu.be/7O0s5AY46U0
I appreciate all the congratulations for our Series A! I also want to make sure we don't forget an important truth
Funding is not the finish line.
We're grateful for the resources we have, and my promise is that we'll continue to do everything in our power to make a difference
Funding is not the finish line.
We're grateful for the resources we have, and my promise is that we'll continue to do everything in our power to make a difference
AI Proteins has closed a $41.5 million Series A financing to accelerate the development of de novo #miniproteins! The round was led by Mission BioCapital and SANTÉ, with robust participation from existing investors.
See the official press release for details:
www.businesswire.com/news/home/20...
See the official press release for details:
www.businesswire.com/news/home/20...
November 20, 2025 at 8:03 PM
I appreciate all the congratulations for our Series A! I also want to make sure we don't forget an important truth
Funding is not the finish line.
We're grateful for the resources we have, and my promise is that we'll continue to do everything in our power to make a difference
Funding is not the finish line.
We're grateful for the resources we have, and my promise is that we'll continue to do everything in our power to make a difference
The next chapter for AI Proteins @aiproteins.com is officially underway! I'm absolutely delighted to share that we’ve closed a $41.5M Series A led by Mission BioCapital and Santé Ventures.
endpoints.news/boston-biote...
endpoints.news/boston-biote...
Exclusive: AI Proteins raises $42M Series A, and will launch miniproteins into hub-and-spoke model
AI Proteins raises $42M Series A for minibinder drug development, led by Mission BioCapital & Santé Ventures. CEO Chris Bahl aims to target TNFR1 with first candidate.
endpoints.news
November 18, 2025 at 3:55 PM
The next chapter for AI Proteins @aiproteins.com is officially underway! I'm absolutely delighted to share that we’ve closed a $41.5M Series A led by Mission BioCapital and Santé Ventures.
endpoints.news/boston-biote...
endpoints.news/boston-biote...
Now, we’re using these capabilities to develop purpose-built #miniprotein medicines designed to match the complexity of human disease.
November 11, 2025 at 5:06 PM
Now, we’re using these capabilities to develop purpose-built #miniprotein medicines designed to match the complexity of human disease.
This is the foundation for our next chapter at @aiproteins.com. We’ve industrialized the process of creating #miniproteins de novo while fully controlling every aspect of their activity and properties.
November 11, 2025 at 5:06 PM
This is the foundation for our next chapter at @aiproteins.com. We’ve industrialized the process of creating #miniproteins de novo while fully controlling every aspect of their activity and properties.
In this talk, I explain how our #miniproteins can interact with as many targets as needed to deliver the exact therapeutic outcome that patients require. This level of sophistication is unprecedented and will impact indications across oncology, inflammation, and beyond.
November 11, 2025 at 5:06 PM
In this talk, I explain how our #miniproteins can interact with as many targets as needed to deliver the exact therapeutic outcome that patients require. This level of sophistication is unprecedented and will impact indications across oncology, inflammation, and beyond.
To truly control biology, we need medicines that can engage multiple targets simultaneously, but traditional modalities like small molecules and antibodies struggle to do this.
November 11, 2025 at 5:06 PM
To truly control biology, we need medicines that can engage multiple targets simultaneously, but traditional modalities like small molecules and antibodies struggle to do this.
Biology is dizzyingly complex, and yet almost every medicine humanity has ever made acts on a single target in the body. Just a handful can interact with two distinct targets, and these are some of the most exciting treatments to enter the clinic in the past decade.
November 11, 2025 at 5:06 PM
Biology is dizzyingly complex, and yet almost every medicine humanity has ever made acts on a single target in the body. Just a handful can interact with two distinct targets, and these are some of the most exciting treatments to enter the clinic in the past decade.
Reposted by Chris Bahl
Join us in Room 181, Building 68 @mit.edu on October 22nd 2025 @ 7pm EDT to see @grocklin.bsky.social present a mind blowing amount of data and learn what becomes possible at this scale
"Predicting protein folding stability and aggregation propensity using large-scale experiments"
bpdmc.org
"Predicting protein folding stability and aggregation propensity using large-scale experiments"
bpdmc.org
schedule
introduction and membership
Boston Protein Design and Modeling Club (BPDMC) is a community of computational protein engineers and modelers from both academia and industry. While we are based in Boston...
bpdmc.org
October 17, 2025 at 8:27 PM
Join us in Room 181, Building 68 @mit.edu on October 22nd 2025 @ 7pm EDT to see @grocklin.bsky.social present a mind blowing amount of data and learn what becomes possible at this scale
"Predicting protein folding stability and aggregation propensity using large-scale experiments"
bpdmc.org
"Predicting protein folding stability and aggregation propensity using large-scale experiments"
bpdmc.org
We're looking for a mass spec expert to join our team at @aiproteins.com! This position is ideal for a freshly-minted PhD grad (or someone who will graduate within the next 6 months or less), or a rockstar scientist who earned their skills on the job in biotech
We're #hiring a Scientist in Mass Spectrometry!
Apply today or share this post with your network: www.linkedin.com/jobs/view/42...
(ignore what linkedin says - the search is still open)
Interested? Please email your CV to: careers@aiproteins.bio
Apply today or share this post with your network: www.linkedin.com/jobs/view/42...
(ignore what linkedin says - the search is still open)
Interested? Please email your CV to: careers@aiproteins.bio
AI Proteins hiring Scientist in Mass Spectrometry Miniproteins and Bioconjugates in Greater Boston | LinkedIn
Posted 8:20:30 PM. The Company:AI Proteins is a Boston-based biotechnology company focused on the de novo design and…See this and similar jobs on LinkedIn.
www.linkedin.com
September 3, 2025 at 5:47 PM
We're looking for a mass spec expert to join our team at @aiproteins.com! This position is ideal for a freshly-minted PhD grad (or someone who will graduate within the next 6 months or less), or a rockstar scientist who earned their skills on the job in biotech
Reposted by Chris Bahl
🎥 Neste videocast produzido junto do @ieausp.bsky.social, tive uma conversa inspiradora com o Anderson Soares (UFG), @alexandre-cf.bsky.social e o @cdbahl.com sobre como a IA está moldando o futuro da biologia e da saúde humana. Assista aqui 👉 www.youtube.com/watch?v=qQbZ...
Inteligência Artificial Aplicada às Ciências da Vida
YouTube video by Instituto de Estudos Avançados da USP
www.youtube.com
September 1, 2025 at 4:00 AM
🎥 Neste videocast produzido junto do @ieausp.bsky.social, tive uma conversa inspiradora com o Anderson Soares (UFG), @alexandre-cf.bsky.social e o @cdbahl.com sobre como a IA está moldando o futuro da biologia e da saúde humana. Assista aqui 👉 www.youtube.com/watch?v=qQbZ...
Reposted by Chris Bahl
Congratulations to Dr. James Bowman on his promotion to Chief Technology Officer!
www.businesswire.com/news/home/20...
www.businesswire.com/news/home/20...
www.businesswire.com
August 26, 2025 at 2:39 PM
Congratulations to Dr. James Bowman on his promotion to Chief Technology Officer!
www.businesswire.com/news/home/20...
www.businesswire.com/news/home/20...
It’s a privilege to be building @aiproteins.com together with James and our unbelievably talented and dedicated team of people, all striving to make a difference in the world through our technology
www.businesswire.com/news/home/20...
www.businesswire.com/news/home/20...
www.businesswire.com
August 26, 2025 at 2:17 PM
It’s a privilege to be building @aiproteins.com together with James and our unbelievably talented and dedicated team of people, all striving to make a difference in the world through our technology
www.businesswire.com/news/home/20...
www.businesswire.com/news/home/20...
As our first CTO at @aiproteins.com, James will lead the continued acceleration of our platform capabilities in addition to the design, testing and optimization of many novel #miniprotein drug candidates
August 26, 2025 at 2:17 PM
As our first CTO at @aiproteins.com, James will lead the continued acceleration of our platform capabilities in addition to the design, testing and optimization of many novel #miniprotein drug candidates
Our mission is to industrialize drug discovery to create programmable, #denovo protein-based medicines that help patients across a wide range of diseases
August 26, 2025 at 2:17 PM
Our mission is to industrialize drug discovery to create programmable, #denovo protein-based medicines that help patients across a wide range of diseases
James has been one of the key architects of this vision since day one, and his insight and leadership these past ~4 years has shaped the discovery engine that powers @aiproteins.com today
August 26, 2025 at 2:17 PM
James has been one of the key architects of this vision since day one, and his insight and leadership these past ~4 years has shaped the discovery engine that powers @aiproteins.com today
What began as an idea — that we could scale de novo protein design — is now a fully-operational platform that integrates generative #AI with automated production and characterization in the wet lab
August 26, 2025 at 2:17 PM
What began as an idea — that we could scale de novo protein design — is now a fully-operational platform that integrates generative #AI with automated production and characterization in the wet lab
James joined my academic lab at the @ipiproteins.bsky.social in January of 2020 as a postdoc focused on #miniprotein de novo design and engineering. Less than 2 years later, James and I left academia together to found @aiproteins.com along with an incredible team of people from my former lab.
August 26, 2025 at 2:17 PM
James joined my academic lab at the @ipiproteins.bsky.social in January of 2020 as a postdoc focused on #miniprotein de novo design and engineering. Less than 2 years later, James and I left academia together to found @aiproteins.com along with an incredible team of people from my former lab.
I am overjoyed to announce that James Bowman has been promoted to Chief Technology Officer at @aiproteins.com!
🧵👇
🧵👇
August 26, 2025 at 2:17 PM
I am overjoyed to announce that James Bowman has been promoted to Chief Technology Officer at @aiproteins.com!
🧵👇
🧵👇
This was a lot of fun - thanks so much @yossefbaidi.bsky.social and @fang-xie.bsky.social for the great conversation, and for your passion and excitement for biotech and entrepreneurship!
During this episode, @fang-xie.bsky.social and I interview @cdbahl.com, co-founder and CEO of @aiproteins.com. We discuss with Chris his interest in protein science and how he started his academic lab at the @ipiproteins.bsky.social.
July 12, 2025 at 4:10 PM
This was a lot of fun - thanks so much @yossefbaidi.bsky.social and @fang-xie.bsky.social for the great conversation, and for your passion and excitement for biotech and entrepreneurship!
Reposted by Chris Bahl
Super excited to share a new preprint from our lab on design of small-molecule binding proteins using neural networks! The paper has a bit of everything. A new graph neural network, new design algorithms, and experimental validation. www.biorxiv.org/content/10.1...
🧵🧪
🧵🧪
Zero-shot design of drug-binding proteins via neural selection-expansion
Computational design of molecular recognition remains challenging despite advances in deep learning. The design of proteins that bind to small molecules has been particularly difficult because it requ...
www.biorxiv.org
April 28, 2025 at 3:22 PM
Super excited to share a new preprint from our lab on design of small-molecule binding proteins using neural networks! The paper has a bit of everything. A new graph neural network, new design algorithms, and experimental validation. www.biorxiv.org/content/10.1...
🧵🧪
🧵🧪
Reposted by Chris Bahl
#IPISeminar alert 🔔 Friday at 2 p.m. ET, Chris Bahl of AI Proteins will share the challenges of incorporating #artificialintelligence into #proteindesign & the impact reimagined #miniproteins can have on therapeutics. Join us through the QR code or follow the Zoom link on our calendar! rb.gy/xcee9l
May 1, 2025 at 2:08 PM
#IPISeminar alert 🔔 Friday at 2 p.m. ET, Chris Bahl of AI Proteins will share the challenges of incorporating #artificialintelligence into #proteindesign & the impact reimagined #miniproteins can have on therapeutics. Join us through the QR code or follow the Zoom link on our calendar! rb.gy/xcee9l
And most importantly, a huge thank you to the phenomenal team at @aiproteins.bsky.social
Your dedication, ingenuity, and relentless pursuit of innovation are the driving force behind the amazing work we do. It's a privilege to lead such a talented group and to share our achievements with the world
Your dedication, ingenuity, and relentless pursuit of innovation are the driving force behind the amazing work we do. It's a privilege to lead such a talented group and to share our achievements with the world
April 15, 2025 at 4:26 PM
And most importantly, a huge thank you to the phenomenal team at @aiproteins.bsky.social
Your dedication, ingenuity, and relentless pursuit of innovation are the driving force behind the amazing work we do. It's a privilege to lead such a talented group and to share our achievements with the world
Your dedication, ingenuity, and relentless pursuit of innovation are the driving force behind the amazing work we do. It's a privilege to lead such a talented group and to share our achievements with the world
I'm so grateful to Lily James Olds, Leonie Hoerster and Allegra Pearl from TED Conferences for providing such incredible support
April 15, 2025 at 4:26 PM
I'm so grateful to Lily James Olds, Leonie Hoerster and Allegra Pearl from TED Conferences for providing such incredible support